R
R

Roche


財經新聞

Test makers target monkeypox market as cases surge

By Natalie Grover LONDON, June 3 (Reuters) - Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world's first major outbreak of the viral infection outside of Africa. The scramble started last month, much like early 2020 when companies rushed to make kits to help diagnose COVID-19, creating a multibillion-dollar boon for test makers.
A
R
Q

European shares retreat from pre-war levels as investors hit pause

* STOXX 600 declines for first time in four days * Commodity-linked sectors outperform * Belgium's Kinepolis slips as finance chief exits * Cracks widen in EZ economy as war rages on By Shreyashi Sanyal and Anisha Sircar March 30 (Reuters) - European shares retreated after three straight sessions of gains on Wednesday, as investors paused to take stock of the outcome of Russia-Ukraine peace talks.
R
E
F
U
G

European shares fall after three days of gains as Roche weighs

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) March 30 (Reuters) - European shares fell on Wednesday, pulled lower by Swiss drugmaker Roche, with the STOXX 600 index retreating after three straight sessions of cautious gains that were driven by hopes of a breakthrough in Russia-Ukraine peace talks.
R
E
F
U
G

Scandal-hit Credit Suisse shakes up board with Schwan exit

By Silke Koltrowitz ZURICH, March 21 (Reuters) - Credit Suisse shook up its board on Monday, including the departure of its influential vice chair Severin Schwan, as it attempts to draw a line under a series of damaging scandals. Switzerland's second largest bank said that Schwan, 54, who was its lead independent director as well as chief executive of Roche ROG.S , would not stand for re-election to the board of directors at Credit Suisse's annual general meeting on April 29. Schwan faced critic
C
R
U

Credit Suisse vice chair faces re-election opposition -FT

ZURICH, Feb 9 (Reuters) - Credit Suisse CSGN.S Vice Chair Severin Schwan will face opposition from some major shareholders if he stands for re-election to the board of the embattled Swiss bank in April, the Financial Times reported on Wednesday. The FT said the investors were concerned about Schwan leading pharmaceuticals and diagnostics group Roche ROG.S , where he is chief executive, while at the same time acting as the vice-chair of Switzerland's second largest bank.
C
R

Tech and healthcare help European shares above one-month highs

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * STOXX 600 set to end 2021 21.7% higher, fell 4% in 2020 * CNH Industrial hits record high * Defensives lead gains * Roche up after approval for COVID-19 products (Updates with closing prices) By Anisha Sircar Dec 27 (Reuters) - European shares ended higher in thin trading on Monday, led by gains in technology and healthcare stocks, with Roche rising on regulatory approval for COVID-19-r
R
R
C
U
E
F
U
G

EU regulator builds Omicron defences with approvals of Vir, Sobi drugs

* EMA approves Kineret and Xevudy for COVID-19 treatment * Kineret for adults with pneumonia, lung failure risk * Xevudy for adults, adolescents at risk of severe disease By Pushkala Aripaka and Amna Karimi Dec 16 (Reuters) - The European Union's drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK GSK.L and Vir Biotechnology VIR.O and another from Swedish drugmaker Sobi SOBIV.ST , as the bloc builds its defences against Omicron.
A
G
G
P
R
R
S

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

ZURICH, Nov 26 (Reuters) - Roche ROG.S shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's NOVN.S nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.
N
R

Dovish Fed taper, now hawkish BoE?

Nov 4 - A look at the day ahead from Danilo Masoni. Well done Mr. Powell! The Federal Reserve Chair looks to have managed to sell the dialling back of the bank's massive stimulus programme as a dovish taper and investors can now return to the joys of stock markets at record highs. The U.S. policy package contained no nasty surprises — the $15 billion reduction in monthly purchases was consensual and the inflation is "transitory" message was reiterated.
C
N
R
S
U

UK Stocks-Factors to watch on Aug. 20

Aug 20 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening 11 points higher on Friday, according to financial bookmakers, with futures FFIc1 up 0.22%. * ASTRAZENECA: AstraZeneca AZN.L said its antibody therapy met the main goal of preventing COVID-19 infection in a late-stage study. * MARKS & SPENCER: British retailer Marks & Spencer MKS.L said it expected its annual profit to be above forecasts after its food division outperformed expectations and shoppers started returning to its clothe
A
M
R
R
B
U



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明